New PARP inhibitor veliparib showed benefit as first-line treatment for ovarian cancer

https://www.facingourrisk.org/XRAY/veliparib-treatment-may-delay-progression-of-ovarian-cancer

Full article: https://www.nejm.org/doi/full/10.1056/NEJMoa1909707

Treatment with veliparib may benefit women with advanced ovarian cancer. A clinical trial shows that this new PARP inhibitor may delay progression of cancer when combined with chemotherapy and when continued alone as a maintenance therapy. (8/18/20)

Questions To Ask Your Health Care Provider

What are the best treatments for my ovarian cancer given my personal and family history?
Should I consider having genetic testing for inherited cancer mutations?
What are my options for maintenance therapy after chemotherapy?
What type of side effects should I expect from a PARP inhibitor?
Do I qualify for any clinical trials?

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.